GIANG VU: Open Payments
NPI 1386733483 · TACOMA, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,282 in 151 payments from 23 companies in 2025. Trend: 2023 $1,533 · 2024 $2,457 · 2025 $3,282
Food & beverage: $3,282
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 52 | $894 |
| Axsome Therapeutics, Inc. | 27 | $562 |
| Corcept Therapeutics | 11 | $257 |
| Novo Nordisk Inc | 7 | $235 |
| Lundbeck LLC | 11 | $166 |
| Amgen Inc. | 6 | $145 |
| Neurocrine BioSciences, Inc. | 1 | $133 |
| Janssen Pharmaceuticals, Inc | 4 | $115 |
| Lilly USA, LLC | 4 | $108 |
| Otsuka America Pharmaceutical, Inc. | 4 | $99 |
Products named: Sunosi, VRAYLAR, QULIPTA, REXULTI, Korlym, Ozempic, INGREZZA, OTEZLA.
Industry payments across WA — which companies pay providers there.
